VYGR Voyager Therapeutics, Inc.

9.73
-0.65  -6%
Previous Close 10.38
Open 10.15
Price To book 2.19
Market Cap 261.27M
Shares 26,852,000
Volume 217,169
Short Ratio 10.26
Av. Daily Volume 106,630

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b trial onoging. Interim data released December 7, 2016. Cohort 3 data due 3Q 2017. Placebo-controlled trial to commence 4Q 2017.
VY-AADC01
Advanced Parkinson’s disease

Latest News

  1. Voyager Therapeutics Announces Clinical Trial Update with VY-AADC01 for Advanced Parkinson’s Disease
  2. ETFs with exposure to Voyager Therapeutics, Inc. : June 19, 2017
  3. Voyager Therapeutics to Attend Upcoming Investor Conferences
  4. Voyager Therapeutics, Inc. :VYGR-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
  5. Voyager Therapeutics Selects Lead Clinical Candidate for Huntington’s Disease
  6. Edited Transcript of VYGR earnings conference call or presentation 9-May-17 9:30pm GMT
  7. Voyager Therapeutics reports 1Q loss
  8. Voyager Therapeutics Reports First Quarter 2017 Financial Results and Corporate Highlights
  9. Investor Network: Voyager Therapeutics, Inc. to Host Earnings Call
  10. Voyager Therapeutics to Host First Quarter 2017 Financial Results and Corporate Highlights Conference Call
  11. Voyager Therapeutics Announces Additional Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease
  12. 4 Sell-Ranked Drug Stocks Investors Should Avoid Ahead of Earnings
  13. Voyager Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : VYGR-US : April 11, 2017
  14. ETFs with exposure to Voyager Therapeutics, Inc. : April 5, 2017
  15. Voyager Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : VYGR-US : March 28, 2017
  16. Voyager Therapeutics, Inc. :VYGR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  17. Edited Transcript of VYGR earnings conference call or presentation 15-Mar-17 12:30pm GMT